172 related articles for article (PubMed ID: 24578251)
1. Sourcing quality-of-life weights obtained from previous studies: theory and reality in Korea.
Bae S; Bae EY; Lim SH
Patient; 2014; 7(2):141-50. PubMed ID: 24578251
[TBL] [Abstract][Full Text] [Related]
2. A Review of Utility Measurement Methods Used in Pharmacoeconomic Submissions to HIRA in South Korea: Methodological Consistency and Areas for Improvement.
Hong J; Bae EY
Pharmacoeconomics; 2021 Oct; 39(10):1109-1121. PubMed ID: 34318442
[TBL] [Abstract][Full Text] [Related]
3. The use of QALY weights for QALY calculations: a review of industry submissions requesting listing on the Australian Pharmaceutical Benefits Scheme 2002-4.
Scuffham PA; Whitty JA; Mitchell A; Viney R
Pharmacoeconomics; 2008; 26(4):297-310. PubMed ID: 18370565
[TBL] [Abstract][Full Text] [Related]
4. Evaluation on the first 2 years of the positive list system in South Korea.
Park SE; Lim SH; Choi HW; Lee SM; Kim DW; Yim EY; Kim KH; Yi SY
Health Policy; 2012 Jan; 104(1):32-9. PubMed ID: 22001369
[TBL] [Abstract][Full Text] [Related]
5. Eight-year experience of using HTA in drug reimbursement: South Korea.
Bae EY; Hong JM; Kwon HY; Jang S; Lee HJ; Bae S; Yang BM
Health Policy; 2016 Jun; 120(6):612-20. PubMed ID: 27086557
[TBL] [Abstract][Full Text] [Related]
6. What Is the Evidence from Past National Institute of Health and Care Excellence Single-Technology Appraisals Regarding Company Submissions with Base-Case Incremental Cost-Effectiveness Ratios of Less Than £10,000/QALY?
Carroll C; Houten R; Boland A; Kaltenthaler E; Dickson R
Value Health; 2018 Mar; 21(3):341-350. PubMed ID: 29566842
[TBL] [Abstract][Full Text] [Related]
7. Data Configuration and Publication Trends for the Korean National Health Insurance and Health Insurance Review & Assessment Database.
Kim HK; Song SO; Noh J; Jeong IK; Lee BW
Diabetes Metab J; 2020 Oct; 44(5):671-678. PubMed ID: 33115211
[TBL] [Abstract][Full Text] [Related]
8. Trends in the measurement of health utilities in published cost-utility analyses.
Brauer CA; Rosen AB; Greenberg D; Neumann PJ
Value Health; 2006; 9(4):213-8. PubMed ID: 16903990
[TBL] [Abstract][Full Text] [Related]
9. What value health?: A review of health state values used in early technology assessments for NICE.
Stein K; Fry A; Round A; Milne R; Brazier J
Appl Health Econ Health Policy; 2005; 4(4):219-28. PubMed ID: 16466273
[TBL] [Abstract][Full Text] [Related]
10. Role of Health Technology Assessment in Drug Policies: Korea.
Bae EY
Value Health Reg Issues; 2019 May; 18():24-29. PubMed ID: 30419447
[TBL] [Abstract][Full Text] [Related]
11. Health-state utility estimates for health technology assessment: a review of the manufacturers' submissions to the French National Authority for Health.
Hamers FF; Ghabri S; Le Gales C
Expert Rev Pharmacoecon Outcomes Res; 2017 Oct; 17(5):489-494. PubMed ID: 28133977
[TBL] [Abstract][Full Text] [Related]
12. Utility values in National Institute for Health and Clinical Excellence (NICE) Technology Appraisals.
Tosh JC; Longworth LJ; George E
Value Health; 2011 Jan; 14(1):102-9. PubMed ID: 21211492
[TBL] [Abstract][Full Text] [Related]
13. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
14. Which factors enhance positive drug reimbursement recommendation in Scotland? A retrospective analysis 2006-2013.
Charokopou M; Majer IM; Raad Jd; Broekhuizen S; Postma M; Heeg B
Value Health; 2015 Mar; 18(2):284-91. PubMed ID: 25773564
[TBL] [Abstract][Full Text] [Related]
15. Health technology assessment of drugs for rare diseases: insights, trends, and reasons for negative recommendations from the CADTH common drug review.
Janoudi G; Amegatse W; McIntosh B; Sehgal C; Richter T
Orphanet J Rare Dis; 2016 Dec; 11(1):164. PubMed ID: 27908281
[TBL] [Abstract][Full Text] [Related]
16. Using economic evaluations to make formulary coverage decisions. So much for guidelines.
Anis AH; Gagnon Y
Pharmacoeconomics; 2000 Jul; 18(1):55-62. PubMed ID: 11010604
[TBL] [Abstract][Full Text] [Related]
17. A thematic analysis of the strengths and weaknesses of manufacturers' submissions to the NICE Single Technology Assessment (STA) process.
Carroll C; Kaltenthaler E; FitzGerald P; Boland A; Dickson R
Health Policy; 2011 Oct; 102(2-3):136-44. PubMed ID: 21763025
[TBL] [Abstract][Full Text] [Related]
18. Assessment of pharmacoeconomic evaluations submitted for reimbursement in Korea.
Yim EY; Lim SH; Oh MJ; Park HK; Gong JR; Park SE; Yi SY
Value Health; 2012; 15(1 Suppl):S104-10. PubMed ID: 22265055
[TBL] [Abstract][Full Text] [Related]
19. Ixazomib for Relapsed or Refractory Multiple Myeloma: Review from an Evidence Review Group on a NICE Single Technology Appraisal.
Armoiry X; Connock M; Tsertsvadze A; Cummins E; Melendez-Torres GJ; Royle P; Clarke A
Pharmacoeconomics; 2018 Sep; 36(9):1073-1081. PubMed ID: 29582405
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
